Disorders of Kidney Function in Patients with Rheumatoid Arthritis: Drug-Induced Kidney Damage
Downloads
NSAIDs are the drugs that doctors most often prescribe for rheumatoid arthritis. The mechanism of action of NSAIDs is primarily associated with the suppression of the activity of an enzyme called cyclooxygenase. It regulates the synthesis of certain substances that control cellular activity. Due to this, NSAIDs reduce the symptoms of inflammation and pain. As a rule, NSAIDs are used in the treatment of rheumatoid arthritis. They help to cope with chronic pain, inflammation and swelling. But they do not affect the cause of the disease and do not stop the destruction of joints. For most rheumatological diseases, kidney damage portends a poor prognosis and requires aggressive immunosuppressive treatment. On the other hand, it is almost impossible to group NSAIDs by greater or lesser adverse effects on the kidneys - there are very few comparative scientific studies. Thus, it is important to diagnose and treat them at an early stage. But it can be stated that almost all NSAIDs (including selective COX-2 inhibitors) have been described to have adverse effects on the kidneys.
1. AgodoaLY, FrancisME, EggersPW. Association of analgesic use with prevalence of albuminuria and reduced GFR in US adults. Am J Kidney Dis 2008; 51: 573–83.
2. Akhmadovna M. S. Reasons for the Development of Morphostructural Changes in Kidney Cells in Patients with Rheumatoid Arthritis //Vital Annex: International Journal of Novel Research in Advanced Sciences. – 2022. – Т. 1. – №. 5. – С. 396-401.
3. Chang Yu-Kang et al. Increased Risk of End-Stage Renal Disease (ESRD) Requiring Chronic Dialysis is Associated With Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Medicine (Baltimore) 2015; 94 (38): e1362. DOI: 10.1097/MD.0000000000001362.
4. Chang Yu-Kang et al. Increased Risk of End-Stage Renal Disease (ESRD) Requiring Chronic Dialysis is Associated With Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).Medicine (Baltimore) 2015; 94 (38): e1362. DOI: 10.1097/MD.0000000000001362.
5. Cheng Y., Austin S.C., Rocca B., et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002; 296: 539–541.
6. Crofford LJ. COX-1 and COX-2 tissue expression: implications and redictions. J Rheumatol Suppl 1997; 49: 15–9.
7. Davies N.M., Good R.L., Roupe K.A. et al. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error? – not as easy as 1,2,3. J. Pharm. Pharmaceut Sci. 2004; 7(2): 217–226.
8. Dreischulte T, Morales DR, Bell S, Guthrie B. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney Int 2015; 88 (2): 396–403. DOI:10.1038/ki.2015.101. Epub 2015 Apr 15.
9. Dyadyk A.I., Kugler T.E. Side effects of non-steroidal anti-inflammatory drugs. ConsiliumMedicum. 2017; 19 (12): 94–99. DOI: 10.26442/2075-1753_19.12.94-99.
10. Egan K.M., Lawson J.A., Fries S. et al. COX-2 derived prostacycline confers atheroprotection on female mice. Science. 2004; 306: 1954–1957.FANLARI ILMIY JURNALI. – 2022. – Т. 1. – №. 4. – С. 22-27.
11. Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, et al. Treatment of rheumatic inflamma-tory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists // Am J Med. 2005;118(5):52-556.doi:10.1016/j.am-jmed.2005.01.028.
12. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003; 253 (6): 643–52.
13. Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fif-teen patients with AA amyloidosis secondary to inflam-matoryarthritides: a followup report of tolerability and efficacy // Arthritis Rheum. 2003;48(7):2019-2024. doi:10.1002/art.11163.
14. Hцrl W et al. Nonsteroidal Anti-Inflammatory Drugs and the Kidney. Pharmaceuticals (Basel) 2010; 3 (7): 2291–321.
15. Ifuku M., Miyake K., Watanebe M. et al. Various roles of Th cytokine mRNA expression in different formsof glomerulonephritis. Amer. J. Nephrol. 2013; 38 (2):115–123. DOI: 10.1159/000353102.
16. Imig J.D., Ryan M.J. Immune and inflammatory role in renal disease. Compr. Physiol. 2013; 3 (2): 957–976.DOI: 10.1002/cphy.c120028.
17. Ingrasciotta Y, Sultana J, Giorgianni F et al. Association of Individual Non-Steroidal Anti- Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study. PLoS ONE 2015; 10 (4): e0122899. DOI:10.1371/journal.pone. 0122899.
18. Jonson AG. NSAIDs and increased blood pressure. What is clinical significance? Drug Safety 1997; 17: 277–89.
19. Kholmurodovich U. F. Damage to the digestive system when using non-steroidal anti-inflammatory drugs //European journal of modern medicine and practice. – 2022. – Т. 2. – №. 1. – С. 6-16.
20. Kochi M, Kohagura K, Shiohira Y, et al. In-flammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis // PLOS ONE. 2016. doi:10.1371/journal.pone.016022.
21. Kohlhagen J et al. Does regular use of non-steroidal anti-inflammatory drugs increase the risk of renal disease? Nephrology 2002; 7 (1): 5–11.
22. Komhoff M. Cyclooxygenase-2 selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int 2000; 57: 414–22.
23. Komhoff M., Grone H.J., Klein Т. et al.Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function //Am. J. Physiol. 1997. Vol. 272. Р. 460–468.
24. Kurts Ch., Panzer U., Anders H.-J., Rees A.J. The immune system and kidney disease: basic concepts and clinical implications. Nature Rev. Immunol. 2013; 13: 738–753. DOI: 0.1038/nri3523.
25. Masferrer J.L. et al. Selective regulation of cellular cyclooxygenase by dexametason and endotoxin in mice. J. Clin. Invest. 1990; 86: 1375–1379.
26. McLaughlin V.V., Genthner D.E., Panella M.М. et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. NЕJM. 1998; 338: 273–277.
27. Vachiery J.L., Naeije R. Treprostinil: stable long acting prostacyclin analog used for treatment pulmonary arteriolar hypertension. Expert. Rev. Cardiovasc. Ther. 2004; 2: 183–191.
28. Moller B, Pruijm M, Adler S, Scherer A, Villiger PM, Finckh A (2013) Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis, doi: 10.1136/annrheumdis2013– 204078.
29. Moriland L. et. al. Management of rheumatoid arthritis: the historical context. J. Rheumatol. 2001; 286(6): 1431–1452.
30. Musu M et al. Acute nephrotoxicity of NSAID from the foetus to the adult. Eur Rev Med Pharmacol Sci 2011; 15 (12): 1461–72.
31. Nasrallah R., Hebert R.L. Prostacyclin signaling in the kidney: implications for health and disease. Am. J. Physiol. Renal. Physiol. 2005; 289:235–246.
32. Nderitu P, Doos L, Jones PW et al. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Family Practice 2013; 30: 247–55. DOI:10.1093/fampra/cms086.
33. Sanchez-Lorada I.G., Tapia E., Avila-Cazado C. Mild hyperuricemia induces glomerulas hypertension in normal rats // Am. J. Physiol. Renal Physiol. 2002. V. 2823 (5). P. 1105—1110.
34. Satoh T., Ishikava Y., Kataoka Y. et al. CNS-specific prostacyclin ligands as neuronal survival-promoting factors in the brain. Eur. J. Neurosc. 1999; 11: 3115–3124.
35. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993; 44 (3): 643–53.
36. Shankar A, Sun L, Klein BE, et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study // Kidney Int. 2011;80(11):1231-8.doi:10.1038/ki.2011.283.
37. Suárez-Fueyo A., Bradley S.J., Klatzmann D.,Tsokos G.C. T-cells and autoimmune kidney disease.Nature Rev. Nephrol. 2017; 13: 329–343. DOI: 10.1038/nrneph.2017.34.
38. Vane J.R. Inhibition of prostaglandin synthesis as the mechanism of action for aspirin-like drugs. Nature New Biol. 1971; 231: 232–235.
39. Yaxley J, Litfin T. Non-steroidal anti-inflammatories and the development of analgesic nephropathy:a systematic review. RenFail 2016; 38 (9): 1328–34. Epub 2016 Aug 5. DOI:10.1080/0886022X.2016.1216708.
40. Балабанова Р. М. Ревматоидный артрит // В кн.: Руководство по внутренним болезням. Ревматические болезни.Под ред. В. А. Насоновой, Н. В. Бунчука. - М .: Медицина, 1997. - С. 257-295.
41. Жигалов С.А., Марасаев В.В. Влияние селективности и периода полувыведения нестероидных противовоспалительных препаратов на развитие субклинического поражения почек. Современная ревматология. 2016;10(4):28- 34.
42. Игнатовой М.С. Детская нефрология. Руководство для врачей. Под ред. Изд. 3-е, перераб. и доп.М.: МИА. 2011; 696 c. [Detskayanefrologiya. (Pediatricnephrology.) Ed. by M.S. Ignatova. 3d ed. Moscow: MIA. 2011; 696 p. (In Russ.).
43. Калюжина, М. И. Функционально-морфологическое состояние почек у больных ревматоидным артритом / М. И. Калюжина, Е. О. Бухарова, А. Ю.
44. Крель А.А.. Варшавский В.А.. Каневской М.З., Семейкина О.В. Поражение почек у больных ревматоидным артритом // Тер. архив. - 1990. - № 6. - С. 104- 113.6, 15.Boers M. Renaldisordersinrheumatoidarthritis II Arthr. Rheum. - 1990. - Vol.20. - P.57-68.
45. Мустафаева Ш. А. Функционально-Морфологическое Состояние Клеток Почек У Больных Ревмотоидным Артритом //AMALIY VA TIBBIYOT
46. Мустафаева Ш.А.Хроническая болезнь почек у больных ревмотоидным артритом: варианты и факторы риска поражения почек EuropeanjournalofmodernmedicineandpracticeVol. 3 No. 01 (Jan - 2023) ISSN: 2795-921.
47. Насонова ВА, Астапенко МГ. Клиническая ревматология: Руководства для врачей. АМН СССР. М. Медицина, 1989.С.592.
48. Наточина Н.Ю. Тромбоцитарное звено гемостаза и коррекция его нарушений при гломерулонефритах у детей: дис. канд. мед. наук. СПб., 2000. 160 с.
49. Постников С.С., Грацианская А.Н., КостылеваМ.Н. Лекарственные поражения почек. // Педиатрия. - 2016.- Том 95/№ 4. -С. 167-173.
50. Чельцов в.в. НПВС-нефропатии. клин. нефрология. 2011. 5: 17–23. / hel'tsovV.V. NPVS-nefropatii. Klin. nefrologiia. 2011; 5: 17–23.
51. Шатута [и др.] // Бюллетень сибирской медицины. — 2009. — № 8. — С. 51–54.
